This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
CONMED (CNMD) Q1 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
CONMED's (CNMD) first-quarter results gain from strong performance in General Surgery segment and expansion in margins.
Genetic Testing Likely to Drive Invitae's (NVTA) Q1 Earnings
by Zacks Equity Research
Invitae's (NVTA) genetic testing business is expected to have gained from expansion of biopharma partnerships in Q1.
PRA Health (PRAH) Q1 Earnings and Revenues Beat Estimates
by Zacks Equity Research
PRA Health's (PRAH) Clinical Research segment puts up a strong performance in Q1.
What's in the Cards for CVS Health (CVS) in Q1 Earnings?
by Zacks Equity Research
We expect CVS Health (CVS) to have gained from Aetna's addition of new Individual and Group Medicare Advantage members in Q1.
InMode (INMD) to Post Q1 Earnings: What's in the Offing?
by Zacks Equity Research
InMode's (INMD) Q1 performance is likely to have been driven by developments in business segments amid coronavirus-led supply disruptions.
What's in the Cards for DaVita (DVA)This Earnings Season?
by Zacks Equity Research
DaVita (DVA) is expected to have gained from Kidney Care segment in Q1.
What's in Store for Varian Medical (VAR) in Q2 Earnings?
by Zacks Equity Research
Varian's (VAR) solid Oncology platform is expected to have driven fiscal second-quarter performance.
ResMed (RMD) Q3 Earnings Top on Higher Ventilator Sales
by Zacks Equity Research
ResMed's (RMD) adjusted gross margin improves on benefits from changes in product mix, and manufacturing and procurement efficiencies.
Stryker (SYK) Q1 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Stryker's (SYK) first-quarter earnings gain from strong performance at MedSurg and Neurotechnology and Spine units.
Exact Sciences' Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Exact Sciences.
Surmodics (SRDX) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Surmodics (SRDX) registered growth in one of its core units, Invitro Diagnostics, in Q2.
QIAGEN (QGEN) Q1 Earnings to Gain on Growing Test Kit Sales
by Zacks Equity Research
QIAGEN (QGEN) is expected to have gained from increased adoption of testing solutions to identify the SARS-CoV-2 in Q1 amid the coronavirus pandemic.
ABIOMED (ABMD) Q4 Earnings Beat Estimates, Revenues Miss
by Zacks Equity Research
ABIOMED's (ABMD) flagship Impella saw decline in revenues within United States in Q4.
Baxter (BAX) Q1 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Baxter's (BAX) first-quarter earnings benefit from solid segmental performance and growth across all geographies.
BioCryst (BCRX) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
During BioCryst's (BCRX) upcoming Q1 earnings call, investor focus will be on the company's progress with the NDA for its HAE drug, Berotralstat, and the study on galidesivir for COVID-19 disease
Exact Sciences (EXAS) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Exact Sciences (EXAS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Cerner (CERN) Q1 Earnings Beat Estimates, Revenues Miss
by Zacks Equity Research
Cerner (CERN) first-quarter results benefit from gains in Licensed software, Subscriptions and Professional and Managed services units, and international revenue growth.
DexCom (DXCM) Q1 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
DexCom's (DXCM) first-quarter earnings benefit from solid segmental performance.
Is a Beat in Store for Avadel (AVDL) This Earnings Season?
by Zacks Equity Research
On Avadel's (AVDL) Q1 earnings call, investor focus will be on the company's lead candidate, FT218, currently being evaluated to treat excessive daytime sleepiness and cataplexy in narcolepsy patients.
What's in Store for Unum Therapeutics' (UMRX) Q1 Earnings?
by Zacks Equity Research
During Unum Therapeutics' (UMRX) upcoming Q1 earnings call, investor focus will be on the company's progress pertaining to its preclinical program, BOXR1030, for treating solid tumor cancers.
Ecolab (ECL) Q1 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Strength in the Global Industrial and Institutional segments drives Ecolab's (ECL) first-quarter results.
Henry Schein (HSIC) to Report Q1 Earnings: What's in Store?
by Zacks Equity Research
Contribution from Henry Schein's (HSIC) medical business in the form of point-of-care antibody rapid test is likely to have boosted Q1 performance amid the coronavirus pandemic.
What's in Store for Aytu BioScience's (AYTU) Q3 Earnings?
by Zacks Equity Research
On Aytu BioScience's (AYTU) upcoming earnings call, investor focus will be on its distribution right to commercialize the COVID-19 IgG/IgM Rapid Test in North America.
Novavax (NVAX) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
During Novavax's (NVAX) upcoming Q1 earnings call, investor focus will be on the company's progress with its seasonal influenza vaccine candidate, NanoFlu, and the COVID-19 vaccine candidate.
Is a Beat in Store for Abeona (ABEO) This Earnings Season?
by Zacks Equity Research
Abeona's (ABEO) operating expenses are expected to have increased in the first quarter driven by clinical studies on its lead gene therapy candidate.